255 related articles for article (PubMed ID: 27553713)
1. Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.
Fry EA; Taneja P; Inoue K
Int J Cancer; 2017 Feb; 140(3):495-503. PubMed ID: 27553713
[TBL] [Abstract][Full Text] [Related]
2. Clinical applications of mouse models for breast cancer engaging HER2/neu.
Fry EA; Taneja P; Inoue K
Integr Cancer Sci Ther; 2016; 3(5):593-603. PubMed ID: 28133539
[TBL] [Abstract][Full Text] [Related]
3. Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development.
Taneja P; Maglic D; Kai F; Sugiyama T; Kendig RD; Frazier DP; Willingham MC; Inoue K
Cancer Res; 2010 Nov; 70(22):9084-94. PubMed ID: 21062982
[TBL] [Abstract][Full Text] [Related]
4. [Generation and comparison of two genetically engineered mouse models of ErbB2/Neu positive-PTEN deficient breast cancer].
Wang QF; Ding H; Liu BR; Zhang K
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 43(4):427-33. PubMed ID: 25187457
[TBL] [Abstract][Full Text] [Related]
5. Targeting HER2: recent developments and future directions for breast cancer patients.
Wang SC; Zhang L; Hortobagyi GN; Hung MC
Semin Oncol; 2001 Dec; 28(6 Suppl 18):21-9. PubMed ID: 11774202
[TBL] [Abstract][Full Text] [Related]
6. Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis.
Dong Y; Van Tine BA; Oyama T; Wang PI; Cheng EH; Hsieh JJ
Cell Res; 2014 Nov; 24(11):1354-66. PubMed ID: 25267403
[TBL] [Abstract][Full Text] [Related]
7. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
8. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
9. Tumor suppressor ARF inhibits HER-2/neu-mediated oncogenic growth.
Zhang Y; Yang HY; Zhang XC; Yang H; Tsai M; Lee MH
Oncogene; 2004 Sep; 23(42):7132-43. PubMed ID: 15273726
[TBL] [Abstract][Full Text] [Related]
10. Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis.
Zhao H; Martin E; Matalkah F; Shah N; Ivanov A; Ruppert JM; Lockman PR; Agazie YM
Oncogene; 2019 Mar; 38(13):2275-2290. PubMed ID: 30467378
[TBL] [Abstract][Full Text] [Related]
11. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
[TBL] [Abstract][Full Text] [Related]
12. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
[TBL] [Abstract][Full Text] [Related]
13. ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis.
Nie J; Dang S; Zhu R; Lu T; Zhang W
Breast Cancer Res; 2024 Jan; 26(1):19. PubMed ID: 38287441
[TBL] [Abstract][Full Text] [Related]
14. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
[TBL] [Abstract][Full Text] [Related]
15. [The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7].
Zheng L; Ren JQ; Chen Q; Zhang HP; Zhu HG
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):594-7. PubMed ID: 15634518
[TBL] [Abstract][Full Text] [Related]
16. Cooperation between Dmp1 loss and cyclin D1 overexpression in breast cancer.
Zhu S; Mott RT; Fry EA; Taneja P; Kulik G; Sui G; Inoue K
Am J Pathol; 2013 Oct; 183(4):1339-1350. PubMed ID: 23938323
[TBL] [Abstract][Full Text] [Related]
17. Reduced androgen receptor expression accelerates the onset of ERBB2 induced breast tumors in female mice.
Hodgson MC; Vanostran G; Alghamdi S; Poppiti RJ; Agoulnik AI; Agoulnik IU
PLoS One; 2013; 8(4):e60455. PubMed ID: 23593223
[TBL] [Abstract][Full Text] [Related]
18. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer.
Bentires-Alj M; Neel BG
Cancer Res; 2007 Mar; 67(6):2420-4. PubMed ID: 17347513
[TBL] [Abstract][Full Text] [Related]
19. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
20. Dmp1α inhibits HER2/neu-induced mammary tumorigenesis.
Fry EA; Taneja P; Maglic D; Zhu S; Sui G; Inoue K
PLoS One; 2013; 8(10):e77870. PubMed ID: 24205004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
